secwatch.observer — SEC 8-K summary
======================================

Issuer:     Milestone Pharmaceuticals Inc. (MIST)
CIK:        0001408443
Form:       8-K
Filed at:   2026-03-20T23:59:59+00:00
Accession:  0001104659-26-032427
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Milestone Pharma FY2025 net loss $63.1M; CARDAMYST launch on track; cash runway into late 2027
--------------------------------------------------------------------------------

- Net loss of $63.1M ($0.75 per share) for FY2025 vs $41.5M ($0.67) prior year.
- Revenue of $1.5M from CARDAMYST FDA approval milestone under Corxel agreement.
- Commercial expense $28.3M for FY2025; 60-person sales force deployed mid-Feb.
- Pro forma cash $200M including $75M RTW payment and $19M ATM/warrant exercises; runway to late 2027.
- EMA accepted MAA for etripamil; decision expected H1 2027.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1408443/000110465926032427/0001104659-26-032427-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1408443/000110465926032427/tm269403d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-032427

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer